Please see below information about and status of our ongoing clinical trials.

If you are an Eyecare practitioner and would like to refer your patients to us please visit this page. If you are looking to enrol yourself or your children into our trial please click here.


MAP trial

MiSight® Analysis of Progression (MAP) Study

MIST is a 3-year study which involves the evaluation of the MiSight®, in comparison to MiSight 2a and 2b which are all intended to slow the progression of juvenile-onset myopia in children. The principle of applying myopic defocus via a dual focus optical design is the basis for the MiSight soft contact lens. You can read more about the MiSight contact lenses by CooperVision here.

Trial status:

Open for recruitment.

MOSAIC trial

Myopia Outcome Study of Atropine in Children

There is no current therapeutic approach to the control and prevention of myopia, which is expected to affect one in three people worldwide by 2020, and represents the only major cause of blindness that is untreatable.

CHAMP and MOSAIC are the first European trials to explore the efficacy and safety of atropine for myopia prevention in a Caucasian population.

Trial status:

250 subjects enrolled, recruitment completed. Data collection ongoing (expected completion 2023).

Centile charts

CHAMP trial

Children using atropine for reduction of myopia progression

The primary objective of CHAMP is to evaluate the safety & efficacy of 2 concentrations of atropine sulfate ophthalmic solution (0.01% & 0.02%) compared to placebo (vehicle) for the reduction of progression of myopia over a 3-year treatment period.

Trial status:

52 subjects enrolled, recruitment completed. Data collection ongoing (expected completion 2023).

ENIGMA trial

European Nutrition in Glaucoma Management trial

Glaucoma is an age-related neurodegenerative condition that shares associations with cognitive decline, and is one of the major causes of blindness. The focus of the the European Nutrition in Glaucoma Management trial (ENIGMA) is to explore the role of macular pigment (MP), a nutritional biomarker believed to confer neuroprotection along the central nervous system, in glaucoma. This trial will be a first step to develop a novel nutritional therapy that can halt the progression of the disease, and improve the quality of life of people with glaucoma, such as by giving them back their freedom to safely drive at night.

The ENIGMA trial comprises an 18-month double-masked, randomised and placebo-controlled clinical trial to determine the potential benefits of MP supplementation for one of the leading causes of blindness in Ireland and globally.

Trial status:

Recruitment completed. Data collection completed in Sep 2020. Conducting data analysis.